Who we are
Tetra Health is a leading Australian clinic network that facilitates responsible access to treatments for patients in every State and Territory in Australia.
Tetra also provides education for healthcare providers on the prescription of various treatments and manages treatment outcomes, providing ongoing support and patient monitoring from specialist nurses and authorised prescribers.
Tetra’s network of partners have managed over 30,000 global patients with a diverse list of indications and comorbidities while collecting quality patient data, and Tetra has leveraged this international experience and intellectual property to become a leading service provider in Australia.
Tetra’s proprietary patient engagement and monitoring solution enables secure patient onboarding, automation of Special Approval Scheme and Therapeutic Goods Administration applications, better patient management and ongoing monitoring and support through Tetra’s specialist nurses and follow up physician consultations.
What We Do
Tetra’s clinic network connects patients and medical practitioners to specialist prescribers of medical cannabis medicines. Through this network, Tetra collects valuable real-world evidence to assist medical practitioners to make evidence-based, data-driven treatment decisions. Tetra currently services a number of healthcare providers and their patients across multiple disease states, offering premium health services, including;
- CPD Accredited Training
- Streamlined Patient Access
- Nurse Specialist Support
- Personalised Treatment Plans
- Patient Monitoring
- Treatment Progress Reports
- Patient Assessment
- Data Management
- 1-800 Support Line
Tetra’s experience in Australia to date has demonstrated the ability to achieve better patient outcomes, to build supportive systems for healthcare providers, and support producers of medicines on the foundation of clinical research, controlled administration and continuous care.
Tetra is led by a team of experts on its Senior Management team, Board of Directors and Medical Advisory Board with years of relevant and diverse experience across global medical cannabis and healthcare industries.
Medical Advisory Board
Professor Andrew McLachlan
Professor Andrew McLachlan is the Head of School and Dean of Pharmacy in the Sydney Pharmacy School and a Member of the Order of Australia. He is currently the Program Director of the NHMRC Centre for Research Excellence in Medicines and Ageing. He is the former Professor of Pharmacy (Aged Care) (2006-2018) in the then Faculty of Pharmacy and at Concord Hospital’s Centre for Education and Research on Ageing.
Andrew is a pharmacist, academic and researcher experienced in clinical and experimental pharmacology and research on the quality use of medicines. His research focuses on understanding the variability in response to medicines and how this can be managed to optimise patient care, particularly in special patient populations such as older people, the very young and the critically ill. He is interested in translating clinical pharmacology research and high quality clinical trial evidence into real-world practice.
Dr Mona Singh
Dr Mona Singh completed her undergraduate study of Medicine in India in 2005, before completing her training in the UK in 2012. Since then, she has been practicing as a GP and was admitted to the Royal Australian College of General Practitioners in 2013. Mona takes an integrative and holistic approach to her practice, which is reflected in her thorough and empathetic approach to her patients.
Mona is a medical editor at CESPHN, and a member of their Clinical Advisory Committee. Mona is also Medical Director of BUPA, and a BPUA (MBVS) Education Committee Member.
Professor Stephen Clarke
Professor Stephen Clarke is a medical oncologist, pharmacologist and translational researcher with major clinical and research interests in gastrointestinal and thoracic cancers and pharmacology. He is a medical oncologist at the Northern Cancer Institute and Royal North Shore Hospital, Director of Cancer Services at Northern Sydney Local Health District and Professor of Medicine at the University of Sydney.
Stephen is Head of the NSW committee of the RACP and is Oncology Advisor to the Department of Veterans Affairs as well as a Member of the Repatriation Pharmaceutical Review Committee.
Associate Professor Kellie Charles
Associate Professor Kellie Charles is a cancer pharmacologist with a research interest in the interactions between inflammation, the immune system and cancer chemotherapy outcomes. She is the Head of the Cancer Therapeutics Research Laboratory at the University of Sydney and 15 years of clinical and translational research experience.
Dr Samuel Banister
Dr Samuel Banister is a Senior Research Fellow in the School of Chemistry at The University of Sydney. He brings more than 10 years of experience drug discovery and cannabinoid science to the role. Dr Banister has recently returned to Australia after completing postdoctoral training in radiochemistry, positron emission tomography (PET) imaging, and drug development at Stanford University. His research is centred on the use of cannabinoids for the treatment of epilepsy, affective disorders, and pain.